Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
990.68
-7.55 (-0.76%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
40
41
Next >
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years
November 02, 2023
Biotech may be in a slump, but this innovator holds enormous promise as a potential wealth escalator.
Via
The Motley Fool
Regeneron Reports Third Quarter 2023 Financial and Operating Results
November 02, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema
November 01, 2023
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program highlight durability of visual improvements and consistent safety across extended dosing intervals and patient...
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech
November 01, 2023
Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic.
Via
Talk Markets
Exposures
COVID-19
$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
October 31, 2023
Via
Benzinga
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
October 30, 2023
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Earnings Scheduled For November 2, 2023
November 02, 2023
Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
Via
Benzinga
Regeneron Pharmaceuticals Unusual Options Activity
November 01, 2023
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $6,000 Today
October 19, 2023
Via
Benzinga
MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer
October 30, 2023
New results from a targeted therapy and immuno-oncology company show the promising potential efficacy of one of its first-in-class treatments.
Via
Benzinga
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
October 30, 2023
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.
Via
The Motley Fool
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
October 28, 2023
The U.S.
Via
Benzinga
Exposures
Product Safety
SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff
October 27, 2023
The happy talk in Sanofi's press release didn't help with analysts, who have been disappointed in the company and SNY stock all year.
Via
InvestorPlace
Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss
October 26, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Price Over Earnings Overview: Regeneron Pharmaceuticals
October 17, 2023
Via
Benzinga
IBD's 100 Best ESG Companies For 2023
October 27, 2023
The companies on our list combine high sustainability scores and top stock ratings.
Via
Investor's Business Daily
Regeneron Announces Investor Conference Presentations
October 25, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Stock-Split Watch: Could These 2 Growth Stocks Be Next?
October 25, 2023
Neither company has discussed it, at least not yet.
Via
The Motley Fool
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
October 25, 2023
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
October 22, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
October 21, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
October 21, 2023
The venerable pharmaceutical companies' shares have slumped this year.
Via
The Motley Fool
Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
October 20, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
October 18, 2023
Via
Benzinga
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
October 18, 2023
The company can begin a pivotal study of its treatment for cardiomyopathy.
Via
Investor's Business Daily
Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN
October 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
October 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Why REGENERON PHARMACEUTICALS (NASDAQ:REGN) Deserves Consideration as a Quality Investment.
October 17, 2023
This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN)
Via
Chartmill
Healthcare Portfolio Focus Stocks
October 16, 2023
The macro news has been a steady headwind with rising rates offering 5% risk-free treasury yields.
Via
Talk Markets
Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
October 16, 2023
Via
Benzinga
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.